T-cell-replete haploidentical transplantation in acute myeloid leukemia

Luca Castagna , Raynier Devillier , Norbert Vey (1) , Didier Blaise (2, 1)

1 CRCM - Centre de Recherche en Cancérologie de Marseille
2 Service d’Hématologie [Institut Paoli Calmettes, Marseille]

In the last decade, the number of haploidentical stem cell transplantation has increased because of the widespread use of T-cell-replete platforms developed worldwide. Acute myeloid leukemia (AML) is the main indication to perform allogeneic stem cell transplantation. Here, we reviewed the clinical results obtained using T-cell-replete platforms in different clinical situations such as first or further complete remission, refractory disease, and in the elderly population. Overall, the toxic profile of T-cell-replete haploidentical transplantation is similar to transplantation from other donors, with positive aspects such as a reduced incidence of chronic graft versus-host disease. Leukemia-free survival and overall survival are also similar. In conclusion, T-cell-replete haploidentical transplantation represents a new frontier in the treatment landscape of AML, lessening problems linked to donor search and ensuring that a donor can be found for all patients in a timely manner. (C) 2018 ISEH Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Domaines: Sciences du Vivant [q-bio]

Luca Castagna, Raynier Devillier, Norbert Vey, Didier Blaise. T-cell-replete haploidentical transplantation in acute myeloid leukemia. Experimental Hematology, 2018, 58, pp.5-16. ⟨10.1016/j.exphem.2017.11.001⟩. ⟨hal-02143586⟩